Zydus Lifesciences starts phase IV EVIDENCES-XI trial

09 Jun 2023 Evaluate

Zydus Lifesciences has commenced Phase of IV Real World Data Registry trial ‘EVIDENCES- XI’ for Saroglitazar Magnesium in NAFLD patients with comorbidities (ClinicalTrials.gov Identifier: NCT05872269).

The Phase IV EVIDENCES- XI trial will enroll around 1500 male and female NAFLD patients with comorbidities (either obesity, type 2 diabetes mellitus, dyslipidemia or metabolic syndrome- 200 patients each). The study duration is around 56 weeks. The primary endpoint is to measure the change in liver stiffness measurement performed by transient elastography from Baseline to Week 52. 

Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company.

Zydus Lifesciences Share Price

1013.75 14.15 (1.42%)
28-Mar-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1620.50
Dr. Reddys Lab 6171.85
Cipla 1494.65
Zydus Lifesciences 1013.75
Lupin 1617.85
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.